| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
¶¶||
From the Division of Nephrology,*
Department of
Medicine, and the Departments of Pathology,
Preventive Medicine,
and Urological
Surgery, §
Vanderbilt University, Nashville;
the Vanderbilt-Ingram Cancer Center,¶
Nashville; and the Nashville VA Medical Center,||
Nashville, Tennessee
Studies in human and animal models have shown that cyclooxygenase (COX)-2 is up-regulated in several epithelial carcinomas including colon, breast, and lung. To elucidate the possible involvement of COX-2 in human bladder cancer we examined the expression of COX isoforms in benign tissue and in bladder carcinoma specimens. Paraffin embedded tissues from 75 patients with urothelial carcinomas were immunostained with specific antibodies raised against COX-1 and COX-2. COX-1 expression was detected in smooth muscle cells in both benign and malignant bladders. COX-2 immunoreactivity was absent in benign tissue and in specimens with low-grade urothelial carcinoma (0/23). In contrast, expression of COX-2 was detected in malignant epithelial cells in 38% (17/47) of specimens with high-grade urothelial carcinomas. Expression of COX-2 in high-grade bladder cancer was confirmed by radioactive in situ hybridization using a COX-2-selective riboprobe. Both immunohistochemistry and in situ hybridization showed COX-2 expression in a small subset of malignant cells. COX-2 mRNA was also expressed in three out of seven malignant urothelial cell lines. These data demonstrate elevated expression of COX-2 in a high percentage of high-grade bladder carcinomas, suggesting a possible role of COX-2 in the progression of bladder urothelial carcinoma and supporting its potential as a therapeutic target in human bladder carcinoma.
This article has been cited by other articles:
 |
|
 |
|
  T. Nakagawa, H. Tanaka, T. Shirakawa, A. Gotoh, Y. Hayashi, K. Hamada, M. Tsukuda, and K.-i. Nibu Cyclooxygenase 2 Promoter-Based Replication-Selective Adenoviral Vector for Hypopharyngeal Cancer Arch Otolaryngol Head Neck Surg, March 1, 2009; 135(3): 282 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Monjazeb, K. P. High, A. Connoy, L. S. Hart, C. Koumenis, and F. H. Chilton Arachidonic acid-induced gene expression in colon cancer cells Carcinogenesis, October 1, 2006; 27(10): 1950 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Saad, P. J. O'Connor, M. H. Mostafa, N. E. Metwalli, D. P. Cooper, G. P. Margison, and A. C. Povey Bladder tumor contains higher n7-methylguanine levels in DNA than adjacent normal bladder epithelium. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 740 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Crist, Z. Zhang, M. You, W. T. Gunning, P. B. Conran, V. E. Steele, and R. A. Lubet Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture Carcinogenesis, May 1, 2005; 26(5): 951 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Klein, C. S. Van Pelt, A. L. Sabichi, J. dela Cerda, S. M. Fischer, G. Furstenberger, and K. Muller-Decker Transitional Cell Hyperplasia and Carcinomas in Urinary Bladders of Transgenic Mice with Keratin 5 Promoter-Driven Cyclooxygenase-2 Overexpression Cancer Res., March 1, 2005; 65(5): 1808 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shirakawa, K. Hamada, Z. Zhang, H. Okada, M. Tagawa, S. Kamidono, M. Kawabata, and A. Gotoh A Cox-2 Promoter-Based Replication-Selective Adenoviral Vector to Target the Cox-2-Expressing Human Bladder Cancer Cells Clin. Cancer Res., July 1, 2004; 10(13): 4342 - 4348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Huguenin, F. Vacherot, L. Kheuang, J. Fleury-Feith, M.-C. Jaurand, M. Bolla, J.-P. Riffaud, and D. K. Chopin Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines Mol. Cancer Ther., March 1, 2004; 3(3): 291 - 298. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Choy and L. Milas Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance? J Natl Cancer Inst, October 1, 2003; 95(19): 1440 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Wallace Nutritional and Botanical Modulation of the Inflammatory Cascade--Eicosanoids, Cyclooxygenases, and Lipoxygenases-- As an Adjunct in Cancer Therapy Integr Cancer Ther, March 1, 2002; 1(1): 7 - 37. [Abstract] [PDF]
|
|
|
|
 |
|
 M. C. Specht, O. N. Tucker, M. Hocever, D. Gonzalez, L. Teng, and T. J. Fahey III Cyclooxygenase-2 Expression in Thyroid Nodules J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 358 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Thomas, Z. K. Ascott, D. Harmey, L. W. Slice, E. Rozengurt, and A. J. Lax Cytotoxic Necrotizing Factor from Escherichia coli Induces RhoA-Dependent Expression of the Cyclooxygenase-2 Gene Infect. Immun., November 1, 2001; 69(11): 6839 - 6845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. P. de Almeida, C. Piche, J. Sirois, and M. Dore Expression of Cyclo-oxygenase-2 in Naturally Occurring Squamous Cell Carcinomas in Dogs J. Histochem. Cytochem., July 1, 2001; 49(7): 867 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ristimaki, O. Nieminen, K. Saukkonen, K. Hotakainen, S. Nordling, and C. Haglund Expression of Cyclooxygenase-2 in Human Transitional Cell Carcinoma of the Urinary Bladder Am. J. Pathol., March 1, 2001; 158(3): 849 - 853. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
